{"pmid":32349033,"title":"Novel biosensor platforms for the detection of coronavirus infection and SARS-CoV-2.","text":["Novel biosensor platforms for the detection of coronavirus infection and SARS-CoV-2.","The recent outbreak of the SARS-CoV-2 pandemic has been causing respiratory diseases globally, damaging wide-ranges of social-economical activities. This virus is transmitted through personal contact and possibly also through ambient air. Effective biosensor platforms for the detection of this virus and the related host response are in urgent demand. These platforms can facilitate routine diagnostic assays in certified clinical labs. They can also be integrated into point-of-care products. Furthermore, environmental biosensors can be designed to detect SARS-CoV-2 in the ambient air or in the intensive care ventilators. Here, we evaluate technical components of biosensors, including the biological targets of recognition, the recognition methods and the signal amplification and transduction systems. Effective SARS-CoV-2 detectors can be designed by adequate combination of these technologies.","J Chin Med Assoc","Liang, Kung-Hao","Chang, Tai-Jay","Wang, Mong-Lien","Tsai, Ping-Hsing","Lin, Ta-Hsien","Wang, Chin-Tien","Yang, De-Ming","32349033"],"abstract":["The recent outbreak of the SARS-CoV-2 pandemic has been causing respiratory diseases globally, damaging wide-ranges of social-economical activities. This virus is transmitted through personal contact and possibly also through ambient air. Effective biosensor platforms for the detection of this virus and the related host response are in urgent demand. These platforms can facilitate routine diagnostic assays in certified clinical labs. They can also be integrated into point-of-care products. Furthermore, environmental biosensors can be designed to detect SARS-CoV-2 in the ambient air or in the intensive care ventilators. Here, we evaluate technical components of biosensors, including the biological targets of recognition, the recognition methods and the signal amplification and transduction systems. Effective SARS-CoV-2 detectors can be designed by adequate combination of these technologies."],"journal":"J Chin Med Assoc","authors":["Liang, Kung-Hao","Chang, Tai-Jay","Wang, Mong-Lien","Tsai, Ping-Hsing","Lin, Ta-Hsien","Wang, Chin-Tien","Yang, De-Ming"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32349033","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1097/JCMA.0000000000000337","topics":["Diagnosis"],"weight":1,"_version_":1665441658347454464,"score":8.599203,"similar":[{"pmid":32281785,"pmcid":"PMC7158889","title":"Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection.","text":["Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection.","The ongoing outbreak of the novel coronavirus disease (COVID-19) has spread globally and poses a threat to public health in more than 200 countries. Reliable laboratory diagnosis of the disease has been one of the foremost priorities for promoting public health interventions. The routinely used reverse transcription polymerase chain reaction (RT-PCR) is currently the reference method for COVID-19 diagnosis. However, it also reported a number of false-positive or -negative cases, especially in the early stages of the novel virus outbreak. In this work, a dual-functional plasmonic biosensor combining the plasmonic photothermal (PPT) effect and localized surface plasmon resonance (LSPR) sensing transduction provides an alternative and promising solution for the clinical COVID-19 diagnosis. The two-dimensional gold nanoislands (AuNIs) functionalized with complementary DNA receptors can perform a sensitive detection of the selected sequences from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through nucleic acid hybridization. For better sensing performance, the thermoplasmonic heat is generated on the same AuNIs chip when illuminated at their plasmonic resonance frequency. The localized PPT heat is capable to elevate the in situ hybridization temperature and facilitate the accurate discrimination of two similar gene sequences. Our dual-functional LSPR biosensor exhibits a high sensitivity toward the selected SARS-CoV-2 sequences with a lower detection limit down to the concentration of 0.22 pM and allows precise detection of the specific target in a multigene mixture. This study gains insight into the thermoplasmonic enhancement and its applicability in the nucleic acid tests and viral disease diagnosis.","ACS Nano","Qiu, Guangyu","Gai, Zhibo","Tao, Yile","Schmitt, Jean","Kullak-Ublick, Gerd A","Wang, Jing","32281785"],"abstract":["The ongoing outbreak of the novel coronavirus disease (COVID-19) has spread globally and poses a threat to public health in more than 200 countries. Reliable laboratory diagnosis of the disease has been one of the foremost priorities for promoting public health interventions. The routinely used reverse transcription polymerase chain reaction (RT-PCR) is currently the reference method for COVID-19 diagnosis. However, it also reported a number of false-positive or -negative cases, especially in the early stages of the novel virus outbreak. In this work, a dual-functional plasmonic biosensor combining the plasmonic photothermal (PPT) effect and localized surface plasmon resonance (LSPR) sensing transduction provides an alternative and promising solution for the clinical COVID-19 diagnosis. The two-dimensional gold nanoislands (AuNIs) functionalized with complementary DNA receptors can perform a sensitive detection of the selected sequences from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through nucleic acid hybridization. For better sensing performance, the thermoplasmonic heat is generated on the same AuNIs chip when illuminated at their plasmonic resonance frequency. The localized PPT heat is capable to elevate the in situ hybridization temperature and facilitate the accurate discrimination of two similar gene sequences. Our dual-functional LSPR biosensor exhibits a high sensitivity toward the selected SARS-CoV-2 sequences with a lower detection limit down to the concentration of 0.22 pM and allows precise detection of the specific target in a multigene mixture. This study gains insight into the thermoplasmonic enhancement and its applicability in the nucleic acid tests and viral disease diagnosis."],"journal":"ACS Nano","authors":["Qiu, Guangyu","Gai, Zhibo","Tao, Yile","Schmitt, Jean","Kullak-Ublick, Gerd A","Wang, Jing"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32281785","week":"202016|Apr 13 - Apr 19","doi":"10.1021/acsnano.0c02439","keywords":["lspr","rna virus","biosensors","coronavirus disease","nuclei acids","plasmonic photothermal effect","severe acute respiratory syndrome coronavirus 2"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664636703969640448,"score":227.47206},{"pmid":32293168,"pmcid":"PMC7172500","title":"Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor.","text":["Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor.","Coronavirus disease 2019 (COVID-19) is a newly emerging human infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously called 2019-nCoV). Based on the rapid increase in the rate of human infection, the World Health Organization (WHO) has classified the COVID-19 outbreak as a pandemic. Because no specific drugs or vaccines for COVID-19 are yet available, early diagnosis and management are crucial for containing the outbreak. Here, we report a field-effect transistor (FET)-based biosensing device for detecting SARS-CoV-2 in clinical samples. The sensor was produced by coating graphene sheets of the FET with a specific antibody against SARS-CoV-2 spike protein. The performance of the sensor was determined using antigen protein, cultured virus, and nasopharyngeal swab specimens from COVID-19 patients. Our FET device could detect the SARS-CoV-2 spike protein at concentrations of 1 fg/mL in phosphate-buffered saline and 100 fg/mL clinical transport medium. In addition, the FET sensor successfully detected SARS-CoV-2 in culture medium (limit of detection [LOD]: 1.6 x 10(1) pfu/mL) and clinical samples (LOD: 2.42 x 10(2) copies/mL). Thus, we have successfully fabricated a promising FET biosensor for SARS-CoV-2; our device is a highly sensitive immunological diagnostic method for COVID-19 that requires no sample pretreatment or labeling.","ACS Nano","Seo, Giwan","Lee, Geonhee","Kim, Mi Jeong","Baek, Seung-Hwa","Choi, Minsuk","Ku, Keun Bon","Lee, Chang-Seop","Jun, Sangmi","Park, Daeui","Kim, Hong Gi","Kim, Seong-Jun","Lee, Jeong-O","Kim, Bum Tae","Park, Edmond Changkyun","Kim, Seung Il","32293168"],"abstract":["Coronavirus disease 2019 (COVID-19) is a newly emerging human infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously called 2019-nCoV). Based on the rapid increase in the rate of human infection, the World Health Organization (WHO) has classified the COVID-19 outbreak as a pandemic. Because no specific drugs or vaccines for COVID-19 are yet available, early diagnosis and management are crucial for containing the outbreak. Here, we report a field-effect transistor (FET)-based biosensing device for detecting SARS-CoV-2 in clinical samples. The sensor was produced by coating graphene sheets of the FET with a specific antibody against SARS-CoV-2 spike protein. The performance of the sensor was determined using antigen protein, cultured virus, and nasopharyngeal swab specimens from COVID-19 patients. Our FET device could detect the SARS-CoV-2 spike protein at concentrations of 1 fg/mL in phosphate-buffered saline and 100 fg/mL clinical transport medium. In addition, the FET sensor successfully detected SARS-CoV-2 in culture medium (limit of detection [LOD]: 1.6 x 10(1) pfu/mL) and clinical samples (LOD: 2.42 x 10(2) copies/mL). Thus, we have successfully fabricated a promising FET biosensor for SARS-CoV-2; our device is a highly sensitive immunological diagnostic method for COVID-19 that requires no sample pretreatment or labeling."],"journal":"ACS Nano","authors":["Seo, Giwan","Lee, Geonhee","Kim, Mi Jeong","Baek, Seung-Hwa","Choi, Minsuk","Ku, Keun Bon","Lee, Chang-Seop","Jun, Sangmi","Park, Daeui","Kim, Hong Gi","Kim, Seong-Jun","Lee, Jeong-O","Kim, Bum Tae","Park, Edmond Changkyun","Kim, Seung Il"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293168","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1021/acsnano.0c02823","keywords":["2019-ncov","covid-19","fet","sars-cov-2","biosensor"],"e_drugs":["Lead","Graphite"],"topics":["Diagnosis"],"weight":1,"_version_":1665420446537875458,"score":159.30225},{"pmid":32306853,"title":"Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2.","text":["Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2.","The previous outbreaks of SARS-CoV and MERS-CoV have led researchers to study the role of diagnostics in impediment of further spread and transmission. With the recent emergence of the novel SARS-CoV-2, the availability of rapid, sensitive, and reliable diagnostic methods is essential for disease control. Hence, we have developed a reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for the specific detection of SARS-CoV-2. The primer sets for RT-LAMP assay were designed to target the nucleocapsid gene of the viral RNA, and displayed a detection limit of 10(2) RNA copies close to that of qRT-PCR. Notably, the assay has exhibited a rapid detection span of 30 min combined with the colorimetric visualization. This test can detect specifically viral RNAs of the SARS-CoV-2 with no cross-reactivity to related coronaviruses, such as HCoV-229E, HCoV-NL63, HCoV-OC43, and MERS-CoV as well as human infectious influenza viruses (type B, H1N1pdm, H3N2, H5N1, H5N6, H5N8, and H7N9), and other respiratory disease-causing viruses (RSVA, RSVB, ADV, PIV, MPV, and HRV). Furthermore, the developed RT-LAMP assay has been evaluated using specimens collected from COVID-19 patients that exhibited high agreement to the qRT-PCR. Our RT-LAMP assay is simple to perform, less expensive, time-efficient, and can be used in clinical laboratories for preliminary detection of SARS-CoV-2 in suspected patients. In addition to the high sensitivity and specificity, this isothermal amplification conjugated with a single-tube colorimetric detection method may contribute to the public health responses and disease control, especially in the areas with limited laboratory capacities.","Emerg Microbes Infect","Baek, Yun Hee","Um, Jihye","Antigua, Khristine Joy C","Park, Ji-Hyun","Kim, Yeonjae","Oh, Sol","Kim, Young-Il","Choi, Won-Suk","Kim, Seong Gyu","Jeong, Ju Hwan","Chin, Bum Sik","Nicolas, Halcyon Dawn G","Ahn, Ji-Young","Shin, Kyeong Seob","Choi, Young Ki","Park, Jun-Sun","Song, Min-Suk","32306853"],"abstract":["The previous outbreaks of SARS-CoV and MERS-CoV have led researchers to study the role of diagnostics in impediment of further spread and transmission. With the recent emergence of the novel SARS-CoV-2, the availability of rapid, sensitive, and reliable diagnostic methods is essential for disease control. Hence, we have developed a reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for the specific detection of SARS-CoV-2. The primer sets for RT-LAMP assay were designed to target the nucleocapsid gene of the viral RNA, and displayed a detection limit of 10(2) RNA copies close to that of qRT-PCR. Notably, the assay has exhibited a rapid detection span of 30 min combined with the colorimetric visualization. This test can detect specifically viral RNAs of the SARS-CoV-2 with no cross-reactivity to related coronaviruses, such as HCoV-229E, HCoV-NL63, HCoV-OC43, and MERS-CoV as well as human infectious influenza viruses (type B, H1N1pdm, H3N2, H5N1, H5N6, H5N8, and H7N9), and other respiratory disease-causing viruses (RSVA, RSVB, ADV, PIV, MPV, and HRV). Furthermore, the developed RT-LAMP assay has been evaluated using specimens collected from COVID-19 patients that exhibited high agreement to the qRT-PCR. Our RT-LAMP assay is simple to perform, less expensive, time-efficient, and can be used in clinical laboratories for preliminary detection of SARS-CoV-2 in suspected patients. In addition to the high sensitivity and specificity, this isothermal amplification conjugated with a single-tube colorimetric detection method may contribute to the public health responses and disease control, especially in the areas with limited laboratory capacities."],"journal":"Emerg Microbes Infect","authors":["Baek, Yun Hee","Um, Jihye","Antigua, Khristine Joy C","Park, Ji-Hyun","Kim, Yeonjae","Oh, Sol","Kim, Young-Il","Choi, Won-Suk","Kim, Seong Gyu","Jeong, Ju Hwan","Chin, Bum Sik","Nicolas, Halcyon Dawn G","Ahn, Ji-Young","Shin, Kyeong Seob","Choi, Young Ki","Park, Jun-Sun","Song, Min-Suk"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32306853","week":"202017|Apr 20 - Apr 26","doi":"10.1080/22221751.2020.1756698","keywords":["covid-19","sars-cov-2","colorimetric detection","molecular diagnosis","novel coronavirus","reverse transcription-loop-mediated isothermal amplification"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664632501489893377,"score":145.96237},{"pmid":32332061,"title":"Clinical Evaluation of Three Sample-To-Answer Platforms for the Detection of SARS-CoV-2.","text":["Clinical Evaluation of Three Sample-To-Answer Platforms for the Detection of SARS-CoV-2.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now spread across the globe. As part of the worldwide response, many molecular diagnostic platforms have been granted Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) to identify SARS-CoV-2 positive patients. Our objective was to evaluate three sample-to-answer molecular diagnostic platforms (Cepheid Xpert(R) Xpress SARS-CoV-2 [Xpert Xpress], Abbott ID NOW COVID-19 [ID NOW], GenMark ePlex(R) SARS-CoV-2 Test [ePlex]) to determine analytical sensitivity, clinical performance, and workflow for the detection of SARS-CoV-2 in nasopharyngeal swabs from 108 symptomatic patients. We found that the Xpert Xpress had the lowest limit of detection (100% detection at 100 copies/mL), followed by the ePlex (100% detection at 1,000 copies/mL), and the ID NOW (20,000 copies/mL). The Xpert Xpress also had highest positive percent agreement (PPA) when compared to our reference standard (98.3%) followed by the ePlex (91.4%) and ID now (87.7%). All three assays showed 100% negative percent agreement (NPA). In the workflow analysis, the ID NOW produced the most rapid time to result per specimen ( approximately 17 minutes) as compared to the Xpert Xpress ( approximately 46 minutes) and the ePlex ( approximately 1.5 hours), but what the ID NOW gained in rapid results, it lost in analytical and clinical performance. The ePlex had the longest time to results and showed a slight improvement in PPA over the ID NOW. Information about the clinical and analytical performance of these assays, as well as workflow, will be critical in making informed and timely decisions on testing platform.","J Clin Microbiol","Zhen, Wei","Smith, Elizabeth","Manji, Ryhana","Schron, Deborah","Berry, Gregory J","32332061"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now spread across the globe. As part of the worldwide response, many molecular diagnostic platforms have been granted Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) to identify SARS-CoV-2 positive patients. Our objective was to evaluate three sample-to-answer molecular diagnostic platforms (Cepheid Xpert(R) Xpress SARS-CoV-2 [Xpert Xpress], Abbott ID NOW COVID-19 [ID NOW], GenMark ePlex(R) SARS-CoV-2 Test [ePlex]) to determine analytical sensitivity, clinical performance, and workflow for the detection of SARS-CoV-2 in nasopharyngeal swabs from 108 symptomatic patients. We found that the Xpert Xpress had the lowest limit of detection (100% detection at 100 copies/mL), followed by the ePlex (100% detection at 1,000 copies/mL), and the ID NOW (20,000 copies/mL). The Xpert Xpress also had highest positive percent agreement (PPA) when compared to our reference standard (98.3%) followed by the ePlex (91.4%) and ID now (87.7%). All three assays showed 100% negative percent agreement (NPA). In the workflow analysis, the ID NOW produced the most rapid time to result per specimen ( approximately 17 minutes) as compared to the Xpert Xpress ( approximately 46 minutes) and the ePlex ( approximately 1.5 hours), but what the ID NOW gained in rapid results, it lost in analytical and clinical performance. The ePlex had the longest time to results and showed a slight improvement in PPA over the ID NOW. Information about the clinical and analytical performance of these assays, as well as workflow, will be critical in making informed and timely decisions on testing platform."],"journal":"J Clin Microbiol","authors":["Zhen, Wei","Smith, Elizabeth","Manji, Ryhana","Schron, Deborah","Berry, Gregory J"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32332061","week":"202017|Apr 20 - Apr 26","doi":"10.1128/JCM.00783-20","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1665071049749823488,"score":124.893105},{"pmid":32267771,"title":"The Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) Study: Rationale and Design.","text":["The Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) Study: Rationale and Design.","There is broad interest in improved methods to generate robust evidence regarding best practice, especially in settings where patient conditions are heterogenous and require multiple concomitant therapies. Here, we present the rationale and design of a large, international trial that combines features of adaptive platform trials with pragmatic point-of-care trials to determine best treatment strategies for patients admitted to an intensive care unit with severe community-acquired pneumonia (CAP). The trial uses a novel design entitled a randomized embedded multifactorial adaptive platform (REMAP). The design has 5 key features: i.) randomization, allowing robust causal inference; ii.) embedding of study procedures into routine care processes, facilitating enrollment, trial efficiency, and generalizability; iii.) a multifactorial statistical model comparing multiple interventions across multiple patient subgroups; iv.) response-adaptive randomization with preferential assignment to those interventions that appear most favorable, and v.) a platform structured to permit continuous, potentially perpetual enrollment beyond the evaluation of the initial treatments. The trial randomizes patients to multiple interventions within 4 treatment domains: antibiotics, antiviral therapy for influenza, host immunomodulation with extended macrolide therapy, and alternative corticosteroid regimens, representing 240 treatment regimens. The trial generates estimates of superiority, inferiority and equivalence between regimens on the primary outcome of 90-day mortality, stratified by presence or absence of concomitant shock and proven or suspected influenza infection. The trial will also compare ventilatory and oxygenation strategies and has capacity to address additional questions rapidly during pandemic respiratory infections. As of January 2020, REMAP-CAP was approved and enrolling patients in 52 ICUs in 13 countries in 3 continents. In February, it transitioned into pandemic mode with several design adaptations for COVID-19 disease. Lessons learned from the design and conduct of this trial should aid in dissemination of similar platform initiatives in other disease areas. Clinical trial registered with ClinicalTrials.gov (NCT02735707).","Ann Am Thorac Soc","Angus, Derek C","Berry, Scott","Lewis, Roger J","Al-Beidh, Farah","Arabi, Yaseen","van Bentum-Puijk, Wilma","Bhimani, Zahra","Bonten, Marc","Broglio, Kristine","Brunkhorst, Frank","Cheng, Allen C","Chiche, Jean-Daniel","De Jong, Menno","Detry, Michelle","Goossens, Herman","Gordon, Anthony","Green, Cameron","Higgins, Alisa M","Hullegie, Sebastiaan J","Kruger, Peter","Lamontagne, Francois","Litton, Edward","Marshall, John","McGlothlin, Anna","McGuinness, Shay","Mouncey, Paul","Murthy, Srinivas","Nichol, Alistair","O'Neill, Genevieve K","Parke, Rachael","Parker, Jane","Rohde, Gernot","Rowan, Kathryn","Turner, Anne","Young, Paul","Derde, Lennie","McArthur, Colin","Webb, Steven A","32267771"],"abstract":["There is broad interest in improved methods to generate robust evidence regarding best practice, especially in settings where patient conditions are heterogenous and require multiple concomitant therapies. Here, we present the rationale and design of a large, international trial that combines features of adaptive platform trials with pragmatic point-of-care trials to determine best treatment strategies for patients admitted to an intensive care unit with severe community-acquired pneumonia (CAP). The trial uses a novel design entitled a randomized embedded multifactorial adaptive platform (REMAP). The design has 5 key features: i.) randomization, allowing robust causal inference; ii.) embedding of study procedures into routine care processes, facilitating enrollment, trial efficiency, and generalizability; iii.) a multifactorial statistical model comparing multiple interventions across multiple patient subgroups; iv.) response-adaptive randomization with preferential assignment to those interventions that appear most favorable, and v.) a platform structured to permit continuous, potentially perpetual enrollment beyond the evaluation of the initial treatments. The trial randomizes patients to multiple interventions within 4 treatment domains: antibiotics, antiviral therapy for influenza, host immunomodulation with extended macrolide therapy, and alternative corticosteroid regimens, representing 240 treatment regimens. The trial generates estimates of superiority, inferiority and equivalence between regimens on the primary outcome of 90-day mortality, stratified by presence or absence of concomitant shock and proven or suspected influenza infection. The trial will also compare ventilatory and oxygenation strategies and has capacity to address additional questions rapidly during pandemic respiratory infections. As of January 2020, REMAP-CAP was approved and enrolling patients in 52 ICUs in 13 countries in 3 continents. In February, it transitioned into pandemic mode with several design adaptations for COVID-19 disease. Lessons learned from the design and conduct of this trial should aid in dissemination of similar platform initiatives in other disease areas. Clinical trial registered with ClinicalTrials.gov (NCT02735707)."],"journal":"Ann Am Thorac Soc","authors":["Angus, Derek C","Berry, Scott","Lewis, Roger J","Al-Beidh, Farah","Arabi, Yaseen","van Bentum-Puijk, Wilma","Bhimani, Zahra","Bonten, Marc","Broglio, Kristine","Brunkhorst, Frank","Cheng, Allen C","Chiche, Jean-Daniel","De Jong, Menno","Detry, Michelle","Goossens, Herman","Gordon, Anthony","Green, Cameron","Higgins, Alisa M","Hullegie, Sebastiaan J","Kruger, Peter","Lamontagne, Francois","Litton, Edward","Marshall, John","McGlothlin, Anna","McGuinness, Shay","Mouncey, Paul","Murthy, Srinivas","Nichol, Alistair","O'Neill, Genevieve K","Parke, Rachael","Parker, Jane","Rohde, Gernot","Rowan, Kathryn","Turner, Anne","Young, Paul","Derde, Lennie","McArthur, Colin","Webb, Steven A"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267771","week":"202015|Apr 06 - Apr 12","doi":"10.1513/AnnalsATS.202003-192SD","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["iii.","Pneumonia"],"e_drugs":["Macrolides"],"_version_":1664637636108615680,"score":120.39593}]}